Lv3
350 积分 2021-01-20 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
3天前
已完结
TIGIT’s immuno-oncology teachings
14天前
已完结
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
15天前
已完结
IL-6 antibody in $1.4 billion sale
16天前
已完结
Targeting IL-6 in patients at high cardiovascular risk
1个月前
已完结
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial
1个月前
已关闭
Design and Synthesis of KRASG12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically
1个月前
已完结
Eleven clinical trials that will shape medicine in 2026
1个月前
已完结
Definition and classification of cancer cachexia: an international consensus
1个月前
已完结
Gut-directed therapeutics in inflammatory bowel disease
1个月前
已完结
皖公网安备34019202002308
